Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) EBITDA Margin (2016 - 2025)

KalVista Pharmaceuticals' EBITDA Margin history spans 7 years, with the latest figure at 185.25% for Q2 2020.

  • On a quarterly basis, EBITDA Margin rose 10016.0% to 185.25% in Q2 2020 year-over-year; TTM through Jul 2024 was 1520.75%, a N/A change, with the full-year FY2025 number at 1683.36%, down 142922.0% from a year prior.
  • EBITDA Margin hit 185.25% in Q2 2020 for KalVista Pharmaceuticals, up from 583.96% in the prior quarter.
  • Over the last five years, EBITDA Margin for KALV hit a ceiling of 90.77% in Q3 2016 and a floor of 93257.14% in Q1 2016.
  • Historically, EBITDA Margin has averaged 6352.04% across 5 years, with a median of 219.62% in 2019.
  • Biggest five-year swings in EBITDA Margin: tumbled -2324286bps in 2016 and later surged 484171bps in 2018.
  • Tracing KALV's EBITDA Margin over 5 years: stood at 1000.0% in 2016, then surged by 55bps to 446.23% in 2017, then soared by 88bps to 55.63% in 2018, then tumbled by -147bps to 137.24% in 2019, then plummeted by -35bps to 185.25% in 2020.
  • Business Quant data shows EBITDA Margin for KALV at 185.25% in Q2 2020, 583.96% in Q1 2020, and 137.24% in Q4 2019.